Lineage Cell Therapeutics, Inc. Common Stock · Stock-Based Compensation

Latest reported$5.07Mperiod endingJun 30, 2026

LCTX Stock-Based Comp ($0.00 → $5.07M)

Annual stock-based compensation

High-resolution chart · PNG

LCTX stock-based compensation history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Lineage Cell Therapeutics, Inc. Common Stock Stock-Based Compensation — Annual fiscal periods (USD)
Period ending	Stock-Based Compensation (USD)
Dec 31, 2025	4,752,000
Dec 31, 2024	5,077,000
Dec 31, 2023	4,640,000
Dec 31, 2022	4,287,000
Dec 31, 2021	3,519,000
Dec 31, 2020	2,227,000
Dec 31, 2019	3,580,000
Dec 31, 2018	5,402,000
Dec 31, 2017	3,932,000
Dec 31, 2016	7,951,000
Dec 31, 2015	11,050,000
Dec 31, 2014	4,455,420
Dec 31, 2013	3,217,875
Dec 31, 2012	1,282,507
Dec 31, 2011	1,217,522
Dec 31, 2010	638,709
Dec 31, 2009	488,564
Dec 31, 2008	134,518
Dec 31, 2007	151,059
Dec 31, 2006	0
Dec 31, 2005	89,178
Dec 31, 2004	0
Dec 31, 2003	0
Dec 31, 2002	191,920
Dec 31, 2001	0
Dec 31, 2000	0
Dec 31, 1999	0
Dec 31, 1998	0
Jun 30, 1998	0
Jun 30, 1996	0
Jun 30, 1995	0
Jun 30, 1994	0
Jun 30, 1993	0
Jun 30, 1992	0